Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Ipsen Strengthens Early Clinical Pipeline With IRLAB’s Mesdepotem For Levodopa-Induced Dyskinesia
Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.
Poolbeg Pharma's Capital-Light Model For New Anti-Infectives Development
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of severe influenza ready for Phase II studies.
Affinivax's 24-Valent Pneumococcal Vaccine Targets Growing And Changing Market
A potential next-generation, 24-valent, pneumococcal vaccine in development by Affinivax and Astellas has shown strong immunogenicity in a Phase II study and is preparing to enter pivotal Phase III trials; if successful, it will target a growing market currently dominated by big pharma players.